VT VTRS Viatris Loading... : Bullish and Bearish Analyst Opinions

Viatris trades at ~5.5x forward P/E following a major restructuring, debt paydown, and a 170% jump in open job positions. The massive spike in hiring indicates growth rather than maintenance, and the upcoming October FDA date for MR-141 presents a massive TAM opportunity. A deeply undervalued turnaround play with strong institutional backing and a major pipeline catalyst. FDA rejection of MR-141 or failure to execute on the post-restructuring growth strategy.